Christopher Torres
About Christopher Torres
Christopher Torres is the Head of Strategy and Operations Excellence Japan Patient Safety at Bristol Myers Squibb, with extensive experience in strategic planning, integration, and quality assurance within the pharmaceutical industry.
Current Roles at Bristol Myers Squibb
Christopher Torres currently holds two prominent roles at Bristol Myers Squibb. He is the Head of Strategy and Operations Excellence for Japan Patient Safety, based in Tokyo, Japan. Concurrently, he is also the Director of Strategic Planning and Integration in New Jersey, United States. These positions involve overseeing strategic initiatives and operational excellence in patient safety and strategic planning for the company.
Previous Positions at Bristol Myers Squibb
Torres has a rich history with Bristol Myers Squibb, having held several key roles. From 2020 to 2021, he was the Strategic Planning and Integration Lead. Prior to that, he served as WWPS Integration Champion from 2019 to 2020. He also held the positions of Associate Director of External Affairs and PVA Manager, External Affairs, from 2018 to 2021. Furthermore, Torres managed global PQC (Product Quality Complaints) in New Brunswick, New Jersey from 2015 to 2018.
Experience at Chemtura Corporation and Endo Pharmaceuticals
Before joining Bristol Myers Squibb, Torres worked at Chemtura Corporation as a Quality Manager from 2014 to 2015 in East Hanover, NJ. He also spent three years at Endo Pharmaceuticals in Cranbury, NJ, working in Quality Assurance from 2011 to 2014. These roles involved significant responsibilities in quality management and assurance, contributing to the compliance and quality standards of both companies.
Educational Background
Christopher Torres studied at Monmouth University, where he earned a B.S. in Biology. He furthered his education at Rutgers University, obtaining a Masters in Business and Science with a focus on Drug Discovery and Development. Additionally, he completed a Mini MBA in Business Essentials from Rutgers University. These academic credentials have equipped him with a solid foundation in both the scientific and business aspects of the pharmaceutical industry.